Let's Talk Depression

FDA Approved Spravato (Esketamine) Nasal Spray Available at NeuroMend

Posted by Neuromend Team on May 14, 2019 8:08:15 AM

 

Effective immediately, the U.S. Food and Drug Administration has approved the use of Spravato (esketamine) nasal spray for the treatment of treatment-resistant depression, more commonly known as TRD.

Read More

Topics: Spravato, esketamine

Subscribe to Email Updates

Recent Posts

Download Book


Download App List


 

Schedule Free Consultation